Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:54 AM
Ignite Modification Date:
2025-12-25 @ 4:54 AM
NCT ID:
NCT06196918
Eligibility Criteria:
Inclusion Criteria:
* Individuals aged 18-80 years old with highly suspected (as assessed by study surgeon), newly diagnosed, untreated glioma.
* Patients without heart insufficiency, lungs insufficiency, renal insufficiency, hepatic insufficiency, autoimmune diseases and other organ diseases with severe dysfunction.
* Individuals who agree to undergo surgical resection.
* Individuals with dyskinesia after surgery.
* All patients giving written informed consent.
Exclusion Criteria:
* Individuals with age \< 18 years or \> 80 years.
* Patients with heart insufficiency, lungs insufficiency, renal insufficiency, hepatic insufficiency, autoimmune diseases and other organ diseases with severe dysfunction.
* Individuals have acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea), have peptic ulcer and gastrointestinal bleeding in the past 5 years.
* Patients have history of long-term (current) use of anticoagulants, spontaneous intracranial hemorrhage, and venous thromboembolism.
* Individuals have intracranial hemorrhage after surgery, or other active bleeding.
* Postoperative coagulation disorders (INR \>1.5 or platelet counts \< 100x10\^9/L).
* Patients are allergic to Rivaroxaban.
* Pregnancy or breast-feeding women.
* Inability to give written informed consent.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
80 Years
Study:
NCT06196918
Study Brief:
Protocol Section:
NCT06196918